Have a personal or library account? Click to login
Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients Cover

Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients

Radiology and Oncology
Volume 46 (2012): Issue 2 (June 2012)
By: Viljem Kovac,  Matjaz Zwitter and  Tina Zagar  
Open Access
|May 2012

References

  1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603.10.1056/NEJMra050152
    Search in Google Scholar
  2. Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelinrelated peptides levels in patients with malignant mesothelioma. Dis Markers 2012; 32: 123-31.10.1155/2012/430689
    Search in Google Scholar
  3. Robinson BWS, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.10.1016/S0140-6736(05)67025-0
    Search in Google Scholar
  4. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92: 587-93.10.1038/sj.bjc.6602307236208815668716
    Search in Google Scholar
  5. Marinaccio A, Binazzi A, Cauzillo G, Cavone D, Zotti RD, Ferrante P, et al; Italian Mesothelioma Register (ReNaM) Working Group. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007; 43: 2722-8.10.1016/j.ejca.2007.09.01817980576
    Search in Google Scholar
  6. Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009; 100: 1175-83.10.1038/sj.bjc.6604879266998919259084
    Search in Google Scholar
  7. Milano MT, Zhang H. Malignant pleural mesothelioma. A population-based study of survival. J Thorac Oncol 2010; 5: 1841-8.10.1097/JTO.0b013e3181f1cf2b20975379
    Search in Google Scholar
  8. Podobnik J, Kocijancic I, Kovac V, Sersa I. 3T MRI in evaluation of asbestosrelated thoracic diseases - preliminary results. Radiol Oncol 2010; 44: 92-6.10.2478/v10019-010-0027-7342368522933897
    Search in Google Scholar
  9. Gill RR. Imaging of mesothelioma. Recent Results Cancer Res 2011; 189: 27-43.10.1007/978-3-642-10862-4_321479894
    Search in Google Scholar
  10. Peake MD, Entwisle J, Gray SG. Malignant pleural mesothelioma: clinical presentation, radiological evaluation and diagnosis. In: O'Byrne K, Rusch V, editors. Malignant pleural mesothelioma. Oxford: Oxford University Press; 2006. p. 35-60.
    Search in Google Scholar
  11. Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol 2011; 12: 163-72.10.1007/s11864-011-0146-4332183921404104
    Search in Google Scholar
  12. Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 2008; 7: 102-6.10.1510/icvts.2007.166322
    Search in Google Scholar
  13. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, et al; European Respiratory Society/European Society of Thoracic Surgeons Task Force. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-95.10.1183/09031936.00063109
    Search in Google Scholar
  14. Eržen J, Vidmar S, Sok M, Debeljak A, Kecelj P, Kovač V, et al. Surgical treatment of malignant pleural mesothelioma. Experience in Slovenia in the interdisciplinary approach. Radiol Oncol 2005; 39: 123-31.
    Search in Google Scholar
  15. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 3007-13.10.1200/JCO.2008.20.3943
    Search in Google Scholar
  16. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-94.10.1016/S0140-6736(08)60727-8
    Search in Google Scholar
  17. Zwitter M. Dutch statistics on lung cancer: sobering experience for a new approach. J Thorac Oncol 2012; 7: 269-71.10.1097/JTO.0b013e31823ab5fb
    Search in Google Scholar
  18. Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, et al. A phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 2012; 23: 230-8.10.1097/CAD.0b013e32834d7a1c
    Search in Google Scholar
  19. Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2011; Dec 1. [Epub ahead of print]10.1183/09031936.00153611
    Search in Google Scholar
  20. Debevec M, Kovač V, Debeljak A, Eržen J, Remškar Z, Kern I. [Malignant pleural mesothelioma. Analysis of patients in Slovenia 1980-1997]. [Slovenian]. Zdrav Vest 2000; 69: 599-606.
    Search in Google Scholar
  21. Debeljak A, Kecelj P, Kern I, Eržen J, Kovač V, Rott T. Medical thorascopy in pleural malignant mesothelioma. In: Zaltloukal P, Petruželka L, editors. Lung Cancer. Current Topics. Prague: Monduzzi Editore; 2001. p. 81-6.
    Search in Google Scholar
  22. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-51.10.1002/(SICI)1097-0258(20000215)19:3<;335::AID-SIM336>3.0.CO;2-Z
    Search in Google Scholar
  23. Hmeljak J, Coer A. Presence and role of Simian virus 40 (SV40) in malignant pleural mesothelioma. Radiol Oncol 2009; 43: 9-16.10.2478/v10019-009-0009-9
    Search in Google Scholar
  24. Hmeljak J, Kern I, Cor A. No implication of Simian virus 40 in pathogenesis of malignant pleural mesothelioma in Slovenia. Tumori 2010; 96: 667-73.10.1177/030089161009600504
    Search in Google Scholar
  25. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008; 5: 136-47.10.1038/ncponc103918227828
    Search in Google Scholar
  26. Erculj N, Kovac V, Hmeljak J, Dolzan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignan pleural mesothelioma. Ann Oncol 2012; 23: 961-7.10.1093/annonc/mdr32421765044
    Search in Google Scholar
  27. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-42.10.1056/NEJMoa100067820818875
    Search in Google Scholar
  28. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2629-30.10.1200/JCO.2003.11.13612860938
    Search in Google Scholar
  29. Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia. Lung Cancer 2009; 64: 308-13.10.1016/j.lungcan.2008.09.00819004520
    Search in Google Scholar
  30. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25-30.10.1200/JCO.1999.17.1.2510458214
    Search in Google Scholar
  31. Aversa SM, Favaretto AG. Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV. Clin Lung Cancer 1999; 1: 73-7.10.3816/CLC.1999.n.006
    Search in Google Scholar
  32. van Haarst JMW, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86: 342-5.10.1038/sj.bjc.6600118237522711875695
    Search in Google Scholar
  33. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87: 491-6.10.1038/sj.bjc.6600505237615512189542
    Search in Google Scholar
  34. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20: 274-81.10.1200/JCO.2002.20.1.27411773179
    Search in Google Scholar
  35. Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003; 97: 2791-7.10.1002/cncr.1140512767092
    Search in Google Scholar
  36. Andreopoulou E, Ross PJ, O'Brien ME, Ford HE, Priest K, Eisen T, et al. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 2004; 15: 1406-12.10.1093/annonc/mdh35615319247
    Search in Google Scholar
  37. van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer, Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-9.10.1200/JCO.20005.14.58916192580
    Search in Google Scholar
  38. Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005; 28: 223-6.10.1097/01.coc.0000144852.75613.5615923792
    Search in Google Scholar
  39. Berghmans T, Lafitte JJ, Paesmans M, Stach B, Berchier MC, Wackenier P, et al. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer 2005; 50: 75-82.10.1016/j.lungcan.2005.05.00716005104
    Search in Google Scholar
  40. Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol 2008; 26: 1465-71.10.1200/JCO.2007.14.761118349397
    Search in Google Scholar
  41. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24: 1443-8.10.1200/JCO.2005.04.319016549838
    Search in Google Scholar
  42. Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, et al; Pemetrexed Expanded Access Program Investigators. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 2007; 55: 187-94.10.1016/j.lungcan.2006.09.02317092602
    Search in Google Scholar
  43. Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3: 756-63.10.1097/JTO.0b013e31817c73d618594322
    Search in Google Scholar
  44. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19: 370-3.10.1093/annonc/mdm50118156144
    Search in Google Scholar
  45. Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008; 60: 259-63.10.1016/j.lungcan.2007.09.018270265818006112
    Search in Google Scholar
  46. Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008; 3: 1325-31.10.1097/JTO.0b013e31818b174d18978569
    Search in Google Scholar
  47. Sørensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008; 99: 44-50.10.1038/sj.bjc.6604421245303418542078
    Search in Google Scholar
  48. Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, et al. Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 2009; 29: 3441-4.
    Search in Google Scholar
  49. Sørensen JB, Bech C, Sorensen P, Frank H. Phase II study of carboplatin and vinorelbine 1st line treatment in advanced malignant pleural mesothelioma. [Abstract]. J Thorac Oncol 2011; 6(6 Suppl): S1354.-5.
    Search in Google Scholar
  50. Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B, Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 2005; 16: 1129-34.10.1097/00001813-200511000-0001316222156
    Search in Google Scholar
  51. Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 2009; 4: 1148-55.10.1097/JTO.0b013e3181ae280f19546818
    Search in Google Scholar
  52. Zwitter M, Kovac V, Rajer M, Vrankar M, Smrdel U. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial. Anticancer Drugs 2010; 21: 662-8.10.1097/CAD.0b013e32833ab7a020453635
    Search in Google Scholar
  53. Kovac V. Zwitter M. Cisplatin with Alimpta or gemcitabine in long infusion for mesothelioma (AGILI). Available: http://clinicaltrials.gov/ct2/show/NCT01281800
    Search in Google Scholar
  54. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-63.10.1016/j.lungcan.2006.01.00616569462
    Search in Google Scholar
  55. Velez M, Arango BA, Perez CA, Santos ES. Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer. Clin Med Insights Oncol 2012; 6: 117-24.10.4137/CMO.S6248329011022412303
    Search in Google Scholar
  56. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011; 72: 73-7.10.1016/j.lungcan.2010.12.00421216487
    Search in Google Scholar
  57. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, et al. Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey. Lung Cancer 2012; 75: 360-7.10.1016/j.lungcan.2011.08.01121937142
    Search in Google Scholar
  58. Goricar K, Erculj N, Zadel M, Dolzan V. Genetic polymorphisms in homologous recombination repair genes in healthy Slovenian population and their influence on DNA damage. Radiol Oncol 2012; 46: 46-53.10.2478/v10019-012-0001-7342376722933979
    Search in Google Scholar
  59. Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol 2012; 7: 249-56.10.1097/JTO.0b013e318233d6a922031231
    Search in Google Scholar
  60. Erculj N, Kovac V, Hmeljak J, Franko A, Dodič-Fikfak M, Dolzan V. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet Genomics 2012; 22: 58-68.10.1097/FPC.0b013e32834e357222134350
    Search in Google Scholar
DOI: https://doi.org/10.2478/v10019-012-0032-0 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 136 - 144
Published on: May 30, 2012
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
malignant pleural mesothelioma,
incidence,
survival,
chemotherapy,
gemcitabine in prolonged infusion
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2012 Viljem Kovac, Matjaz Zwitter, Tina Zagar, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 46 (2012): Issue 2 (June 2012)